LEM Surgical AG Secures CHF 22 Million in Series B Funding to Ready Robotic System for FDA Submission
Summary
The round, which was strongly oversubscribed, reflects the strong investors confidence in LEM Surgicals differentiated approach.This substantial funding boost is attributed to the enthusiastic participation of new investors from both the United States and Switzerland. The infusion of capital is strategically earmarked to propel the advancement of LEM Surgicals product development initiatives and readiness for FDA submission in the second half of 2024. It underscores the unwavering confidence our investors have in the future success of our groundbreaking technology. "LEM Surgical is at the forefront of shaping the future through the creation of the next generation of robotic surgery platforms. The primary focus of its development efforts is centered around surpassing the capabilities of existing robotic platforms for spine surgery.The company was founded in 2021 by Prof. Dr. Stefan Weber (CEO, CAScination AG), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group), Prof. Dr. Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern) and Yossi Bar (previously Director R&D at Mazor Robotics Ltd).